Vanderbilt University Medical Center https://www.vumc.org has selected Biofourmis https://biofourmis.com, a leader in virtual care and digital therapeutics, for a clinical study to monitor patients in a home like outpatient setting after receiving a oncology drug.
Patients with large B-cell lymphoma will receive CAR-T cell therapy via remote monitoring. Patients receiving CAR-T therapy typically need to remain in the hospital for up to 7 to 10 days after the treatment, primarily to monitor side effects which can be severe and potentially fatal. clinical study to monitor patients in a home-like outpatient setting after receiving a leading oncology drug.
CAR-T therapy is highly effective, but the lengthy hospital stay can add cost to the system and inconvenience to patients, said Olalekan O. Oluwole, MD, Associate Professor of Medicine, Hematology/Oncology at Vanderbilt University.
Dr. Oluwole explained, “By using Remote Patient Management Technology and Telemedicine, we are investigating how patients can remain in a home-like setting while being monitored around the clock instead of in a hospital.”
Instead of remaining in the hospital after receiving the immunotherapy, which is the current standard of care, patients will be discharged to a home-like setting near the medical center.
In addition to periodic physical exams, several vital signs will be continuously monitored through the Biofourmis analytics platform to assist the clinical team detect the side effects of therapy to intervene as appropriate.
The Biofourmis AI powered Biovitals® Platform received clearance from FDA in 2019 as a medical device for ambulatory physiological monitoring. The device continuously collects data from medical grade biosensors to create a personalized view for each subject.
Biofourmis delivers the collected data through a dashboard viewable by clinicians and researchers, who also receive notifications based on vital signs when they deviate from baseline and/or if a study participant has not entered the required blood pressure readings.
Kuldeep Singh Rajput, CEO and Founder of Biofourmis, reports that by using Biofourmis technology, clinicians will be able to detect early signs of an adverse reaction so they can immediately intervene.